The uniqueness and changeability of market dynamics for male breast cancer are influenced in various ways. In contrast to female breast cancer which is more prevalent, there has been an increasing incidence of male one that has led to more attention by the medical and pharmaceutical sectors. Some improved understanding about this neglected aspect of tumor types helps direct the market with regard to better treatment and diagnosis options. This change in public perception resulted from early detection campaigns as well as awareness creation that lead to a rise in proactive approach toward male breast health.
In recent times, developments in medical research and technology have played an instrumental role in shaping the male breast cancer market. There have been improvements in diagnostic tools and imaging techniques hence enabling healthcare providers to diagnose the condition at its earliest stage. As a result, patient outcomes have improved as a transition towards early detection that necessitates targeted therapies plus personalized treatment approaches happened. The response of pharmaceutical companies on this front has involved undertaking research and development with an objective of marketing innovative treatment methods.
Regulatory changes alongside gender-based health disparities mitigation efforts also affect these market dynamics. Recognition by governments/healthcare organizations regarding tailored strategies required for handling men’s breast cancer has transformed into policy amendments supporting research funds allocation, awareness campaigns and enhanced healthcare access. Consequently, this leads to conducive environments that promote collaboration between private-public partnerships aimed at advancing research while ensuring justice within male patients’ healthcare sector.
The current socio-cultural environment also affects how the male breast cancer market is changing dynamically today. The society changing its norms along with gender stereotypes breakdown allows males be open about their health purely encompassing all issues related to their breasts. As such, cultural revolution resulted into increasing number of men who consult doctors as well as undergo screening processes thereby influencing positive growths within markets concerned with such trends. As more people become aware it is likely that they would include men too who will actively take part in regular checks further driving need for tests modalities and therapeutic alternatives.
However, there are still challenges within the male breast cancer market. Insufficient knowledge among both medical practitioners and the general public remains critical barrier to overcome. The lack of routine screenings and delayed diagnoses are typical shortcomings resulting in advanced stages during detection. For that reason, addressing these problems calls for combined efforts through educational programs and creating awareness campaigns which will guarantee timely medical intervention so that everyone can benefit from it.
Male Breast Cancer Market Size was valued at USD 1.43 Billion in 2023. The Global Male Breast Cancer industry is projected to grow from USD 1.82 Billion in 2024 to USD 4.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.27% during the forecast period (2024 - 2032).
Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
The male breast cancer market has been segmented into type, cancer diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
Some of the key players in the male breast cancer market are:
Geographically, the Americas is anticipated to dominate the male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833.
Europe is expected to hold the second largest position in the male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Male Breast Cancer Market, by Type
Male Breast Cancer Market, by Diagnosis
Male Breast Cancer Market, by Treatment
BY Treatment
Male Breast Cancer Market, by Region
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)